徳島大学 教育・研究者情報データベース(EDB)

1. (英) Takeuchi Eiji

   役割	任意
   貢献度	任意
   学籍番号	推奨

2. 荻野 広和([徳島大学.病院.診療科.内科.呼吸器・膠原病内科])

   役割	任意
   貢献度	任意
   学籍番号	推奨

3. (英) Kondo Kensuke

   役割	任意
   貢献度	任意
   学籍番号	推奨

4. (英) Okano Yoshio

   役割	任意
   貢献度	任意
   学籍番号	推奨

5. (英) Ichihara Seiya

   役割	任意
   貢献度	任意
   学籍番号	推奨

6. 國重 道大([徳島大学.大学院医歯薬学研究部.医学域.連携研究部門(医学域).寄附講座系(医学域).地域呼吸器・総合内科学])

   役割	任意
   貢献度	任意
   学籍番号	推奨

7. (英) Kadota Naoki

   役割	任意
   貢献度	任意
   学籍番号	推奨

8. (英) Machida Hisanori

   役割	任意
   貢献度	任意
   学籍番号	推奨

9. (英) Hatakeyama Nobuo

   役割	任意
   貢献度	任意
   学籍番号	推奨

10. (英) Naruse Keishi

    役割	任意
    貢献度	任意
    学籍番号	推奨

11. 軒原 浩

    役割	任意
    貢献度	任意
    学籍番号	推奨

12. 篠原 勉([徳島大学.大学院医歯薬学研究部.医学域.連携研究部門(医学域).寄附講座系(医学域).地域呼吸器・総合内科学])

    役割	任意
    貢献度	任意
    学籍番号	推奨

13. 西岡 安彦([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.呼吸器・膠原病内科学])

    役割	任意
    貢献度	任意
    学籍番号	推奨

(英) An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.

(英) An increased relative eosinophil count (REC) has potential as a predictive biomarker for a beneficial clinical response and outcome to cancer immunotherapies. Therefore, the present study investigated the impact of an increased posttreatment REC on the prognosis of non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). We retrospectively reviewed all 151 patients diagnosed with NSCLC and treated with ICI monotherapy and blood test data between March 2016 and August 2021 at National Hospital Organization Kochi Hospital and Tokushima University. A total of 151 patients with a mean age of 69 years were included. REC after 4 weeks of initial ICI monotherapy was higher than pretreatment REC in 87 patients but not in 64. REC after 4 weeks of the ICI treatment with and without an increased REC were 4.4 and 1.8%, respectively (p < 0.001). Disease control rates (DCR) were significantly higher in patients with than in those without an increased REC (84% vs. 47%, p < 0.001). The median overall survival (OS) of lung cancer patients with or without an increased REC were 674 and 234 days, respectively. A Kaplan-Meier univariate analysis revealed a significant difference in OS between the two groups (p < 0.001). A Cox proportional regression analysis identified an increased REC as an independent predictor of OS (p = 0.003). ICI-treated NSCLC patients with an increased REC after 4 weeks of treatment had a better DCR and prognosis than the other patients examined.

1. (英) Humans
2. (英) Aged
3. (英) Carcinoma, Non-Small-Cell Lung
4. (英) Immune Checkpoint Inhibitors
5. (英) Lung Neoplasms
6. (英) Eosinophils
7. (英) Retrospective Studies
8. (英) Biomarkers

1. (英) PublicationType: Journal Article